AFT new FDA approval could be a shot in the arm

AFT new FDA approval could be a shot in the arm
Analyst sentiment is positive after FDA approval of Maxigesic IV. (Image: Hyloris Pharmaceuticals)
Ben Moore
AFT Pharmaceuticals had a bump in share price on Wednesday morning following approval of its intravenous post-operative pain relief drug by the United States Food and Drug Administration.Following the announcement of the approval of Maxigesic IV, which came in overnight, the stock lifted 16 cents per share to $3.56 at the open on the New Zealand stock exchange (NZX), up from $3.40 at yesterday's close. It has since dipped to $3.50.AFT co-founder and managing director Hartley Atkinson said they were delighted to receive the second appro...

More Markets

International interest on bringing LNG to NZ: Jones
Markets

International interest on bringing LNG to NZ: Jones

Shane Jones says there is interest in a Taranaki LNG terminal, despite local scepticism.

Geopolitical tensions keep NZ sharemarket steady
Markets Market Close

Geopolitical tensions keep NZ sharemarket steady

The S&P/NZX 50 Index closed down 0.10%.

Tom Raynel 18 Jun 2025
Analysts expect THL buyout price to rise
Markets

Analysts expect THL buyout price to rise

BGH Capital’s recent acquisition attempt was rejected for undervaluation.

Gregor Thompson 18 Jun 2025
Govt carbon auction attracts no bids
Markets

Govt carbon auction attracts no bids

No one even registered to take part in the second auction of the year.

Ian Llewellyn 18 Jun 2025